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Community Acquired Pneumonia: A Global Perspective 








It is our pleasure to welcome you to this special edition of Seminars in Respiratory and Critical Care 
Medicine, dedicated to the many facets of community-acquired pneumonia (CAP) and its global 
impact. 
Lower respiratory tract infections and pneumonia remain the leading infectious cause of death 
worldwide and also the most common fatal infection presenting to hospital in both the developed 
and developing world.  
Mortality rates have remained relatively static for the past decades despite advances in diagnostics, 
supportive treatment and the development of new antibiotics. The growing global challenges 
include antibiotic resistance, the emergence of new, antibiotic resistant pathogens, emerging 
pandemic viruses, and the global epidemic of HIV infection which leads to large populations of 
patients being at increased risk of pneumococcal disease and other respiratory infections. 
Meeting these challenges requires a concerted effort on the part of global researchers, the 
pharmaceutical industry, regulators and public health to recognise pneumonia as a key global health 
challenge and to push for improvements in the diagnosis, management and prevention of CAP. 
This issue provides a platform for some of the world’s leading pneumonia experts to describe these 
global challenges and to propose their solutions.  
The first part of the issue will highlight the global impact of CAP, with individual chapters dedicated 
to the Asia-pacific region, Africa and South America. As we point out, while the microbiology of 
community-acquired pneumonia is quite similar between different regions of the world, with 
dominance of S. pneumoniae as the causative pathogen, the approach to healthcare and the 
characteristics of the patients makes the management in these regions markedly different. The 
literature of CAP is heavily skewed towards reports from Europe and North America, as are the 
majority of randomized clinical trials, where patients with CAP are predominantly elderly, with co-
morbid conditions, and cared for in high resource settings. CAP in sub-Saharan Africa, where HIV 
prevalence is high, leads to a marked different in patient characteristics with young patients, often 
with co-infection with Mycobacterium tuberculosis and other opportunistic infections, leading to a 
huge diagnostic challenge in a resource poor setting. Thus diagnostic pathways or treatment 
strategies that rely on medical technology that may be feasible in the West, may be less feasible in 
other global settings. 
 
In the second half of the issue, we review a series of critical emerging issues in the international 
management of CAP. Inevitably, antibiotic resistance is a dominant theme. A decade ago, it would be 
unthinkable to have a section of a CAP monograph dedicated to methicillin resistant Staphylococcus 
aureus (MRSA), but the rapid growth in prevalence of MRSA and the move of MRSA from a hospital-
acquired infection to one prevalent in the community has led to some studies reporting MRSA as a 
dominant pathogen, or at least a significant and common pathogen, worldwide. A detailed 
discussion of the mechanisms of antibiotic resistance is provided, while our chapter on diagnostics 
reviews the potential to identify and predict antibiotic resistance in clinical practice. Antibiotic 
stewardship is an international priority to combat antimicrobial resistance and relies on a 
combination of individual education, improved diagnostics and evidence based guidelines that 
balance the need to cover common pathogens, and the need to use antibiotics rationally.  
Antibiotics are the only therapy in widespread use for community-acquired pneumonia patients, and 
have been since their routine availability in the 1950’s. Reducing mortality and morbidity from CAP 
requires to identification of improved methods of treatment including the potential for anti-
inflammatory and immunomodulatory drugs. A series of recent randomized controlled trials suggest 
that steroids may have a role in a subgroup of CAP patients, although the optimal patient population 
and method of treatment has not been defined. Additional prospects for adjuvant therapies 
including statins, immunoglobulins and stem cells are discussed. 
With an aging population, a large proportion of pneumonia patients will die from complications of 
their co-morbidities rather than directly due to the pneumonia themselves. Among these co-
morbidities, cardiovascular diseases are the predominant cause of death, and cardiovascular events 
are increasing recognised during hospitalization for CAP. The mechanisms for this will be discussed, 
as well as the exciting possibility that we may prevent infection-related deaths by using 
cardioprotective therapies in future. 
We hope you enjoy the unique focus of this issue on the global challenges of the disease, and 
emerging threats of the 21st century.  Community-acquired pneumonia remains common, often 
fatal, neglected in terms of clinical trials and new therapies, and crucial to the daily practice of every 
respiratory and critical care physician worldwide. This collection of reviews highlights the key issues, 
the key research questions and the opportunities for the future.  
 
 
 
 
 
 
